市場調查報告書
商品編碼
1159227
白塞氏病治療藥的全球市場:預測(2022年~2028年)Behcet disease drug Market 2022-2028 |
本報告提供全球白塞氏病治療藥市場相關調查,提供市場概要,以及各藥物類型,各給藥途徑,各地區的趨勢,及加入此市場的主要企業簡介等資訊。
Global Behcet disease drug Market Size, Share & Trends Analysis Report by drug (Corticosteroid, Adalimumab Biosimilar, Infliximab Biosimilar, Apremilast, and Canakinumab) And By Route of Administration (Oral, Intravenous, Intramuscular and Topical), Forecast 2022-2028
The global Behcet disease drug market is anticipated to grow at a CAGR during the forecast period. The exact cause of Behcet disease is unknown to medical experts. They find two factors that may be the reason behind this disease. One is a genetic factor and the other is an environmental factor. Another partial cause of Behcet disease is somewhat a variation in the HLA-B gene. The main task of the HLA gene is to manufacture a type of protein in the body which is responsible for a consistent immune system. Scientists consider the HLB gene as part of the human leukocyte antigen complex. HLA complex plays a crucial task as it distinguishes protein made by my body from protein made by foreign bodies. These foreign bodies are viruses and bacteria. In a total number of people infected with Behcet disease, around one-third of them have been found variation in their HLA-B variation. For instance, in July 2020, Fujifilm Kyowa Kirin biologics has received approval to manufacture adalimumab biosimilar which is first in Japan. This will be used to treat entero-Behcet disease, arthritic psoriasis, and rheumatoid arthritis.
The global Behcet disease drug market is segmented based on drug, and route of administration. Based on drug, the market is segmented into Corticosteroid, Adalimumab Biosimilar, Infliximab Biosimilar, Apremilast And Canakinumab . Based on the route of administration, the market is sub-segmented into Oral, Intravenous, Intramuscular, and Topical. Among these, the Topical medication segment is anticipated to grow at a widespread rate during the forecast period. These medications are applied to ulcers and skin lesions so that pain and discomfort are relieved. Various creams are used on skin and genital lesions. For instance, a study done by scientists at National Eye Institute has discovered a unique population of B cells that puts down the immune system which reduces chronic inflammation. These cells reduced symptoms of eye disease such as autoimmune uveitis. Uveitis is a type of inflammatory eye disease that includes Behcet disease.
Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. Asia Pacific are going to be a good market for Behcet disease drug. Being a populous region, the prevalence of Behcet disease is high in this region. This will be a driver for this market in the coming years. For instance, in March 2021, a study by Alvin F wells, who is a rheumatologist, explained a study that was done on patients with Behcet disease. Among 111 patients, most of them needed corticosteroids, and colchicine, adalimumab, and infliximab medications were used most number of the time. The study was published in the webinar titled 'Expert perspectives on the management of rheumatic diseases: Post ACR convergence 2020'.
The major companies serving the global Behcet disease drug market include AbbVie Inc., Celgene Corp., Cell Medica Ltd., Cohersu biosciences Inc., Geno biopharma Corp.Ltd. and others. For instance, in Sep 2021, Amgen wins a case on copyright infringement which was filed against Novartis Sandoz and Zydus Cadila. This case prevents these companies to use generic versions of apremilast.
Research Methodology
The market study of the global Behcet disease drug market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives as possible, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.
Secondary Sources Include:
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation
The Report Covers: